Patient imagery

About mCRPC & PSMA

Unmet Need

PATIENTS WITH mCRPC URGENTLY NEED DIFFERENT OPTIONS¹

Every day matters. More than half of patients die within 2 years of an mCRPC diagnosis. Patients with mCRPC report overall survival a their number one treatment goal. Every treatment choice matters. With every line of therapy, fewer patients are treated. Of all treated 1L patients, only 55% are treated in 2L, and only 30% are treated in 3L. Despite availability of ARPIs and chemotherapy, as patients progress through lines of therapy, unique treatment options become increasingly limited.

1L, first line; 2L, second line; 3L, third line; ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer.

*With ARPI, chemotherapy, bone-targeted radiation, or immunotherapy.²

Scanning to Determine PSMA Status

MORE THAN 80% OF PATIENTS WITH PROSTATE CANCER ARE PSMA+, MAKING PSMA AN IDEAL DIAGNOSTIC AND THERAPEUTIC TARGET^5,6

PSMA-PET imaging demonstrates high sensitivity and specificity to see PSMA+ metastases^7-10
Once a PSMA-PET scan confirms PSMA+ mCRPC, patients can be treated with a PSMA-targeted radioligand therapy like PLUVICTO¹¹

REGARDLESS OF METASTATIC SITE—BONE, NODAL, OR VISCERAL—PLUVICTO TARGETS PSMA+ CELLS¹²

PSMA PET scans of bone, nodal, and visceral metastases

This research was originally published in J Nucl Med. 2015 Apr; v56: Fig 5 pg 1169-1176. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Help your patients strive for victory by ordering a PSMA-PET scan after only 1 ARPI and 1 taxane

Scan for PSMA. Treat PSMA+ mCRPC with PLUVICTO after 1 ARPI and 1 taxane.¹²

Which of your patients with PSMA+ mCRPC might be able to benefit from PLUVICTO next?

Learn more about identifying appropriate patients

PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.

421024_Shore Short Video 1

Prostate Cancer, PSMA, and PLUVICTO

Watch Dr. Neal Shore, MD, FACS, provide an overview of the role of PSMA-PET, and the targeted therapy PLUVICTO, in mCRPC.

< Previous: Safety Profile

Next: Discover PLUVICTO >

References:
1. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium–177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12)(protocol):1091-1103. doi:10.1056/NEJMoa2107322 2. Shore ND, Laliberté F, Ionescu-Ittu R, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38(8):4520-4540. doi:10.1007/s12325-021-01823-6 3. George DJ, Mohamed AF, Tsai JH, et al. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: a US patient preference survey. Cancer Med. 2023;12(5):6040-6055. doi:10.1002/cam4.5313 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Prostate Cancer V.4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 17, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. doi:10.3389/fonc.2018.00623 6. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-body ⁶⁸Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2020;61(3):405-411. doi:10.2967/jnumed.119.230318 7. Hofman MS, Violet J, Hicks RJ, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825-833. doi:10.1016/S1470-2045(18)30198-0 8. Vlachostergios PJ, Niaz MJ, Sun M, et al. Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer. Front Oncol. 2021;11:630589. doi:10.3389/fonc.2021.630589 9. Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914-920. doi:10.2967/jnumed.114.147413 10. Woythal N, Arsenic R, Kempkensteffen C, et al. Immunohistochemical validation of PSMA expression measured by ⁶⁸Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med. 2018;59(2):238-243. doi:10.2967/jnumed.117.195172 11. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium–177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322 12. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp.